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F
orty years ago, a small group of families founded
an organization that has become known as the
Juvenile Diabetes Research Foundation (JDRF),
a group dedicated to ﬁnding a cure for type 1
diabetes and its complications through the support of
research. JDRF implemented what at the time represented
a distinctive paradigm: the involvement of lay volunteers
in decisions regarding research funding, in developing and
implementing policies pertaining to research directions,
and in providing public advocacy for people with type 1
diabetes. This organizational format was generationally
bold and provided a clear signal that JDRF’s volunteers
desired to partner with the scientiﬁc community and with
all who shared their common agenda of helping individu-
als with type 1 diabetes. Over the years, JDRF has part-
nered with a diverse array of organizations with shared
purpose, including the National Institutes of Health (NIH),
various international funding organizations (e.g., Euro-
pean Association for the Study of Diabetes, Wellcome
Trust, Australia National Health and Medical Research
Council, Canadian Institutes for Health Research, Singa-
pore A*STAR), and other foundations, most notably, the
American Diabetes Association (ADA).
In 2010, the 40th anniversary of JDRF’s founding, it
seems propitious to provide an update relaying the
progress this “community of the caring” has achieved in
helping those with type 1 diabetes, and to call for a
renewed purpose-driven dialogue among the many part-
ners seeking to ﬁnd a cure for this disease. To this end,
JDRF is pleased to partner with Diabetes on a series of
“Perspectives in Diabetes” articles that will inform and
update readers on the current state of research progress in
type 1 diabetes and its complications as well as provide
guidance for the direction of future research efforts on this
disease. The series of articles opened with the contribu-
tion on islet cell transplantation (1), and includes the
discussion of the genetics of type 1 diabetes (2) in this
issue. Other articles in the series will tackle such topics as
the pancreatic pathology, immunotherapies for type 1
diabetes, clinical trials in type 1 diabetes, advances in the
prevention and treatment of diabetic retinopathy, and
-cell development.
Looking back on research advances as well as on the
implementation of improved therapeutics over the past
few decades can, depending on the eye of the beholder, be
viewed as one where the glass is currently either half full
or half empty. In the 1970s, there was a growing appreci-
ation that the etiologies of type 1 and type 2 diabetes were
fundamentally different; that type 1 diabetes was charac-
terized by a distinctive association with the human leuko-
cyte antigens of the major histocompatibility complex as
well as the presence of islet cell autoantibodies (3,4).
Studies by Gepts (5) and others noted that patients with
diabetes of juvenile onset were often characterized by the
presence of a lymphocytic inﬁltrate in the pancreatic
islets. With these results, type 1 diabetes widely became
considered an autoimmune disease resulting from an
immune-mediated destruction of pancreatic -cells in ge-
netically predisposed individuals (6). Today we know that
the pathogenic processes underlying the disease may take
a long time (i.e., months to years) for most individuals, and
the autoimmune attack results in the “silent” -cell loss
until the point of symptomatic onset. Many of the cells of
the immune system that are involved in -cell destruction
have been identiﬁed. We believe that when 50–90% of the
-cells have been destroyed (a facet that appears to vary
depending on age, weight, genetics, and other factors), the
resulting hyperglycemia is diagnosed as diabetes. Chronic
hyperglycemia and dysregulated blood glucose levels lead
to the complications of diabetes—microvascular and ma-
crovascular end-organ damage. Even in this high-level
view, investigators now recognize opportunities to inter-
vene at a variety of stages in the disease process based on
knowledge regarding the natural history of type 1 diabetes
(Fig. 1).
Thanks to the contributions of many scientists, there
have been distinctive successes in type 1 diabetes re-
search. The Diabetes Complications and Control Trial
(DCCT) deﬁnitively showed that tight control of blood
glucose levels prevents the complications of type 1 diabe-
tes (7). The Epidemiology of Diabetes Complications
(EDIC) study, the continuation of the DCCT, continues to
provide signiﬁcant results regarding metabolic memory
and its beneﬁt in preventing complications (8). Islet
transplantation has successfully reversed type 1 diabe-
tes in select (albeit small) groups of patients, even if
only transiently (9). The community has implemented
and learned from a series of type 1 diabetes prevention
trials; we now have a much more informed basis for future
efforts (10,11). And recent trials (e.g., anti-CD3, Rituximab,
and Diamyd) to preserve -cell function in new-onset type
1 diabetic patients have shown promising results (12–15).
This commentary will not recapitulate or discuss these
studies; the various “Perspectives in Diabetes” articles will
thoroughly present these details. The bottom line message
of this series—beyond sharing both words of thanks and
congratulations—is that, today, people diagnosed with
type 1 diabetes are living better and longer (16).
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recently conducted an informal poll of scientists and
asked them to nominate the research highlights of the last
40 years. There were many, many suggestions, but the
lessons learned may be summarized as:
1) Type 1 diabetes is different from other forms of diabetes
because of autoimmunity. We need to halt the autoim-
mune response at every stage of disease.
2) The -cell is the focus of all forms of diabetes. In type
1 diabetes, we will need to replace lost -cells or regrow
new ones.
3) Controlling blood glucose is the key to preventing
complications.
4) There are common pathways that lead to multiple
complications.
Even as these statements highlight research progress,
they also call attention to current challenges, areas of
active investigation, and surprising discoveries to come.
We still have much to learn about the pathways that lead
to type 1 diabetes. We also must identify the environmen-
tal triggers that precipitate and/or propagate the autoim-
mune process. We are only just beginning to appreciate
the extent of heterogeneity of human disease with intrigu-
ing but still early results from the Network for Pancreatic
Organ Donors with Diabetes (nPOD) effort (17). We
need to understand the immune pathways that lead to
disease, to identify better biomarkers, and to develop
immune therapies. We must more fully characterize the
metabolic potential in both new-onset and established
type 1 diabetes. We need to fully elucidate the details of
-cell development. Many active efforts to improve islet
transplantation remain and must be explored. We must
investigate in detail the effects of chronic hyperglycemia at
both a system-wide and an organ-speciﬁc level. These
research activities will, collectively, produce the opportu-
nities required to prevent, treat, and cure type 1 diabetes.
One vital lesson learned from the last 40 years is that the
combined efforts of a great many people will be required to
achieve the goal of a cure for all people with type 1
diabetes. Put another way: partnering creates opportuni-
ties. There is a partnership between the research commu-
nity and the volunteers who participate in clinical
research, serve as advocates, and raise money. Partner-
ships with NIH have supported research consortia, fos-
tered innovative new programs, and made signiﬁcant
research resources available to investigators interested in
studying type 1 diabetes (18). Partnerships among funding
organizations, foundations, and enterprises have increased
opportunities for research in type 1 diabetes. We will con-
tinue to explore different ways to engage research scientists,
drug developers, regulatory agencies, and other funders to
the purpose of helping individuals with type 1 diabetes.
The opportunities to impact this disease have never
been greater. Working together, we will achieve our goal
of a cure.
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FIG. 1. The diagram outlines the natural history of type 1 diabetes and its complications (adapted from ref. 6). Therapeutic goals are mapped for
each stage of disease. AutoAbs, to come from author.
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